MSD (known as Merck in U.S. and Canada) recently announced that the Drug Controller General of India (DCGI) has approved KEYTRUDA (pembrolizumab), MSD’s anti-PD-1 therapy, for the treatment of triple-negative breast cancer and renal cell carcinoma in adults. KEYTRUDA has been approved for high-risk early-stage and metastatic triple-negative breast cancer for select patients who are …
